EMA Dismisses Claims That RWD Is The ‘Wrong Remedy’ For Drug Development Challenges
Executive Summary
The European Medicines Agency has responded to an analysis that argued that generating evidence for decision making in health care using observational real-world data, and thus potentially replacing randomized controlled trials, “is the wrong remedy for the challenges in drug development.”
You may also be interested in...
Global Medical Sciences Group Looks At Benefits, Challenges And Risks Of Using RWD
The non-profit Council for International Organizations of Medical Sciences (CIOMS) has issued draft recommendations on using real-world evidence for the approval, use and reimbursement of medicinal products.
EMA Makes Progress On Real-World Evidence ‘Use Cases’ With HTA Bodies & Payers
The European Medicines Agency is looking at how it can generate real-world evidence on multiple myeloma and non-small cell lung cancer using its new DARWIN EU platform so that the outcomes can also be of use for health technology assessment bodies and payers.
French Regulator At Odds With EMA Over Safety Restrictions For Pseudoephedrine
The product information for all pseudoephedrine-containing medicines in the EU will need to be updated, the European Medicines Agency said.